Lakefront Biotherapeutics completes buyback program, holdings reach 1,985,157 shares
A final weekly repurchase of 107,804 shares between October 12 and 16, 2026 completed the June 9, 2026 program, lifting Lakefront's own-share holding to 1,985,157.
Lakefront Biotherapeutics NV disclosed in an October 20, 2026 Form 6-K that the repurchase program announced on June 9, 2026, has been fully completed.1
Between October 12 and October 16, 2026, Lakefront repurchased 107,804 shares via a discretionary mandate to an independent financial intermediary, at an average price of 26.48 euros for a total of 2,854,365.69 euros.1 As of market close on October 16, 2026, Lakefront held 1,985,157 of its own ordinary shares.1
That final window followed four other weekly disclosures that built toward completion of the program:
Between October 5 and October 9, 2026, Lakefront repurchased 126,322 shares at an average price of 26.26 euros for a total of 3,317,407.94 euros, bringing its holding to 1,877,353 shares.2
Between September 28 and October 2, 2026, Lakefront repurchased 117,437 shares for 3,051,866.51 euros at an average of 25.99 euros, lifting its holding to 1,751,031 shares.3
Between September 21 and 25, 2026, Lakefront repurchased 106,060 shares for 2,795,740.67 euros, averaging 26.36 euros, reaching a holding of 1,633,594 shares.4
Between September 14 and 18, 2026, Lakefront repurchased 108,679 shares for 2,608,832.08 euros at an average of 24.00 euros, bringing its holding to 1,527,534 shares.5
In each window, purchases spanned the XAMS, CEUX, AQEU and TQEX venues. Lakefront describes itself as a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need, with a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.